Epidemiological Trends of Fungal Pulmonary Infections Post-COVID-19

Muhammad Ayaz Ahmad; Pirya Kumari; Muhammad Rumman Sikandar; Junaid Islam Baig

doi:10.70749/ijbr.v3i6.1623

Authors

Muhammad Ayaz Ahmad Department of Surgery, Shahida Islam Teaching Hospital, Lodhran, Pakistan
Pirya Kumari Department of Family Medicine, Dow University of Health Sciences, Karachi, Pakistan
Muhammad Rumman Sikandar Department of Medicine, Al-Saeed Medical Complex, Rahim Yar Khan, Pakistan
Junaid Islam Baig Department of Medicine, Family Hospital Daska, Pakistan

DOI:

https://doi.org/10.70749/ijbr.v3i6.1623

Keywords:

Fungal lung infection, COVID-19, post-viral complications, aspergillosis, mucormycosis, corticosteroids, diabetes, pulmonary mycoses, secondary infection, epidemiology

Abstract

Background: Fungal infections of the lungs have developed into a significant concern after COVID-19, especially for patients with predisposing risks like diabetes and previous use of corticosteroids. The combination of clinical signs with viral pneumonia frequently results in missing the diagnosis and negative consequences. To assess the epidemiological characteristics, risk factors, clinical presentation, and outcomes of patients who developed fungal pulmonary infections after recovering from COVID-19. Methods: This was a cross-sectional study conducted from July 2023 to July 2024 at the department of Medicine, DHQ hospital, Lodhran and it included 82 post-COVID patients with pulmonary fungal infections. Demographic information, comorbidities, treatment history of COVID-19, classification of the fungal infection, and the outcomes of the disease were analyzed in SPSS version 25. Statistical relations were tested using the chi-square test and Fisher’s exact test. Results: Most of the patients were males (65.9%) and above 40 years. The diabetes mellitus incidence (52.4%) and history of corticosteroid use (68.3%) were markedly linked with fungal infection. Most frequent pathogens were aspergillus (45.1%) and mucormycosis (26.8%). The most prevalent symptoms were cough, fever, and dyspnea. The recovery rate was at 74.4% and mortality rate was at 14.6%. Conclusion: Fungal pulmonary infections post-COVID-19 are linked with severe disease and high morbidity, especially in patients with diabetes or who received immunosuppressive therapy. Early recognition and targeted treatment are crucial to improve outcomes.

Downloads

Download data is not yet available.

References

Zhao, P., et al., Epidemiology of respiratory pathogens in patients with acute respiratory infections during the COVID‐19 pandemic and after easing of COVID‐19 restrictions. Microbiology Spectrum, 2024. 12(11): p. e01161-24.

https://doi.org/10.1128/spectrum.01161-24

Jeha, J., et al., Green Fungus Challenges in Post-COVID Health Landscape. Integrative Biomedical Research (Former Journal of Angiotherapy), 2024. 8(2): p. 1-10.

https://doi.org/10.25163/angiotherapy.829463

Ibe, C. and A.A. Otu, Post COVID-19 and fungal pathogens coinfection in Africa–current status and future directions. The Microbe, 2024: p. 100152.

https://doi.org/10.1016/j.microb.2024.100152

Vitale, R.G., et al., An overview of COVID-19 related to fungal infections: what do we know after the first year of pandemic? Brazilian Journal of Microbiology, 2022. 53(2): p. 759-775.

https://doi.org/10.1007/s42770-022-00704-6

Sibi, D., et al., Post-COVID-19 Fungal Diseases and Emerging Antifungal Resistance. W J Heal Med, 2023. 1(1): p. 1004.

https://doi.org/10.13188/2332-4120.1000041

Sethuraman, N., Epidemiology and Management of Mucormycosis in India–Pre-and Post-COVID-19. Journal of Association of Pulmonologist of Tamil Nadu, 2021. 4(2): p. 69-74.

https://doi.org/10.4103/japt.japt_42_21

Gong, X., et al., The Road Ahead: Advancing Antifungal Vaccines and Addressing Fungal Infections in the Post-COVID World. ACS Infectious Diseases, 2024. 10(10): p. 3475-3495.

https://doi.org/10.1021/acsinfecdis.4c00245

Wu, Y., et al., Epidemiological study of post-pandemic pediatric common respiratory pathogens using multiplex detection. Virology Journal, 2024. 21(1): p. 168.

https://doi.org/10.1186/s12985-024-02441-8

Murray, H.C., et al., Prevalence, risk factors, and outcomes of secondary infections among hospitalized patients with COVID-19 or post–COVID-19 conditions in Victoria, 2020-2023. International Journal of Infectious Diseases, 2024. 145: p. 107078.

https://doi.org/10.1016/j.ijid.2024.107078

Muthu, V., et al., Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. Mycopathologia, 2021. 186(6): p. 739-754.

https://doi.org/10.1007/s11046-021-00584-8

Tayabali, K., H. Pothiwalla, and S. Narayanan, Epidemiology of COVID-19–associated mucormycosis. Current Fungal Infection Reports, 2023. 17(2): p. 156-175.

https://doi.org/10.1007/s12281-023-00464-2

Rana, G., et al., Massive hemoptysis causing mortality in a post COVID-19 infected Asian male patient: presenting as pulmonary mucormycosis, pulmonary tuberculosis and later sino-nasal mucormycosis. Respiratory Medicine Case Reports, 2021. 34: p. 101511.

https://doi.org/10.1016/j.rmcr.2021.101511

Kang, J.S., Changing trends in the incidence and clinical features of Pneumocystis jirovecii pneumonia in non-HIV patients before and during the COVID-19 era and risk factors for mortality between 2016 and 2022. Life, 2023. 13(6): p. 1335.

https://doi.org/10.3390/life13061335

Avdeeva, M.G., et al., Fungal complications with the new coronavirus infection COVID-19. Epidemiology and Infectious Diseases, 2021. 26(6): p. 252-269.

https://doi.org/10.17816/eid108872

Cattaneo, L., et al., Invasive fungal infections in hospitalized patients with COVID-19: A non-intensive care single-centre experience during the first pandemic waves. Journal of Fungi, 2023. 9(1): p. 86.

https://doi.org/10.3390/jof9010086

Ganesan, N. and S. Sivanandam, Histomorphological features of mucormycosis with rise and fall of COVID-19 pandemic. Pathology-Research and Practice, 2022. 236: p. 153981.

https://doi.org/10.1016/j.prp.2022.153981

Kim, D., et al., No change of Pneumocystis jirovecii Pneumonia after the COVID-19 pandemic: Multicenter Time-Series analyses. Journal of Fungi, 2021. 7(11): p. 990.

https://doi.org/10.3390/jof7110990

Faiyazuddin, M., et al., Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review. Frontiers in Immunology, 2023. 14: p. 1264502.

https://doi.org/10.3389/fimmu.2023.1264502

G Alshahawey, M., et al., New insights on mucormycosis and its association with the COVID-19 pandemic. Future science OA, 2022. 8(2): p. FSO772.

https://doi.org/10.2144/fsoa-2021-0122

Jakubec, P., et al., Pulmonary complications after COVID-19. Life, 2022. 12(3): p. 357.

https://doi.org/10.3390/life12030357